AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05834361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delayed vaginal administration of carboprost methylate
Description: In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
Study NCT05484349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine Hydrochloride
Description: Tizanidine Hydrochloride 2 mg Tid for 12 consecutive weeks and were followed up for 12 weeks
Study NCT05484349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tizanidine Hydrochloride Placebo
Description: Tizanidine Hydrochloride Placebo Comparator 1 tablet Tid for 12 consecutive weeks and were followed up for 12 weeks
Study NCT06540664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture needles
Description: Auricular Acupuncture needles 5 days in 2 weeks
Study NCT05228093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curative-intent endoscopic necrectomy followed by reconstruction using the posterior pedicle nasal septum and floor mucoperiosteum flap
Description: Radical endoscopic necrectomy was performed under general anesthesia using the endoscopic endonasal approach. And the reconstruction of the nasopharyngeal defect use the nasal septum and floor mucoperiosteum flap. Antibiotic therapy based on the result of bacterial cultivation before the surgery was administered for 5-7 days after surgery. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid, and endoscopic nasal cleanup was performed every 2-4 weeks until the flap was completely epithelialized and the entire defect was relined.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery.
Study NCT05228093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Debridement guided by nasopharyngeal endoscopy and excision of the radiation-induced necrotic tissues were performed every 1 or 2 weeks. Patients are prescribed regional perfusion with recombinant human epidermal growth factor derivative liquid (Watsin Genetech Ltd, Shenzhen, Guangdong, P.R. China) to keep the wound humid. Other conservative treatment included daily nasopharynx rinsing with 2% aquae hydrogeniidioxide (5-10 mL each time) or saline (50-100 mL each time) and antibiotic therapy (metronidazole or ornidazole) guided by the culture results was also performed synchronously. Intravenous nutrition and systematic antibiotic therapy were also performed if indicated and necessary. In addition, patients can receive hyperbaric oxygen therapy when conditions permit.~Patients who were assessed as non-healing at 3 months after treatment will underwent salvage surgery.
Study NCT06540664 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Auricular Acupuncture needles
Description: Sham Auricular Acupuncture needles 5 days in 2 weeks
Study NCT05098210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen Peptide Vaccine
Description: Given IM
Study NCT05098210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05098210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Description: Given IM
Study NCT05098210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05098210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05098210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05098210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05098210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05098210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT05098210 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET or PET/CT
Study NCT06328881 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06328881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation training
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06328881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06328881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient's condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT05282446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INV-202
Description: tablet
Study NCT05282446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablet
Study NCT06017388 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: We will propose a hypnotic induction followed by a suggestion of mystical experience (based on Lynn \& Evans, 2017).
Study NCT06017388 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: We will propose the neutral reading of a mystical expetience suggestion (based on Lynn \& Evans, 2017).
Study NCT06442644 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Live music in the intensive care unit
Description: To test a patient-tailored live music intervention's effect on stress reduction in adult, critically ill patients admitted to the intensive care unit.
Study NCT05639621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accompaniment
Description: presence of a person freely chosen by the patient, who will escort in a visual and tactile way during the endoscopic procedure
Study NCT05727943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clioquinol
Description: add on clioquinol to concomitant ASM
Study NCT05660915 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermediate approach
Description: The area between superior mesenteric vein and superior mesenteric artery was defined as the intermediate area and dissection was performed in this area to achieve the removal of the uncinate process of pancreas.
Study NCT05660915 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard approach
Description: The key point of surgery in the standard approach group was to first reveal portal vein-superior mesenteric vein and gradually complete the the resection of the uncinate process of pancreas based on the reference of portal vein-superior mesenteric vein.
Study NCT06489665 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Experimental Intervention
Description: Mammography in the radiology department is commonly performed using General Electrics Medical Systems Senographe Essential device
Study NCT06177236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cervical cancer screening
Description: The aim of this project was to determine the effect of clinic or self-sampling on attendance, attitudes, and anxiety in cervical cancer screening.
Study NCT04691297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escape
Description: The ESCAPE intervention consists of five components:1) behavioral counseling, 2) the use of NRT, 3) digital SNC 4) decision aid about LDCT screening, and 5) a letter and educational materials sent to the primary care provider.
Study NCT04691297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Participants in the standard care arm (brief advice and referral to quit line), will be referred to the MA Quitline which provides free NRT by the study team and will receive an educational brochure related to lung cancer screening.
Study NCT01539174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01539174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01539174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01539174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT01539174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT01539174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01539174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT06280456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: 10 mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation with different drainage clamping time.
Study NCT06114563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirulina yogurt
Description: High cardiometabolic risk volunteers will be asked to consume 2 yogurts with spirulina, each containing 2 g spirulina, daily for 8 weeks, without any other change in their dietary habits and physical activity.
Study NCT06114563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional yogurt
Description: High cardiometabolic risk volunteers will be asked to consume 2 conventional yogurts (without spirulina), daily for 8 weeks, without any other change in their dietary habits and physical activity.
Study NCT05566002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterization
Description: RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP >20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
Study NCT05383651 — intervention group
Intervention type: DEVICE
Intervention: bellavista 1000
Description: observational use of Bellavista 1000 ventilator in adult ventilated patients
Study NCT05383651 — intervention group
Intervention type: DEVICE
Intervention: bellavista 1000 neo
Description: observational use of Bellavista 1000 ventilator in neonatal ventilated patients
Study NCT05581589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Description: Undergo pelvic lymph node dissection
Study NCT05581589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Cystectomy
Description: Undergo radical cystectomy
Study NCT05581589 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Given IV
Study NCT05656807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go NAPSACC Enhanced
Description: Centers will receive the Go NAPSACC program as well as an online weight management intervention that focuses on personal weight management strategies. Participants will have access to materials that will support their adoption of evidence-based strategies for their weight management or loss goal. Behavior change strategies used are meant to increase intervention adherence and improve weight loss.
Study NCT05656807 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go NAPSACC
Description: Go NAPSACC is an online evidence-based behavioral intervention that supports centers as they adopt center-wide healthy weight practices. It anticipates producing change in the child care environment through fostering best practices in center provisions, practices, policies, and professional development around child nutrition and physical activity and in turn foster healthier habits in the children in their care.
Study NCT06385314 — intervention group
Intervention type: OTHER
Intervention: Collecting data with oral health related quality of life, dental anxiety and state anxiety
Description: Collecting data through surveys regarding the patient's oral health related quality of life, dental anxiety and state anxiety before the fixed partial dentures that need to be removed for various clinical reasons are removed.
Study NCT05359705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DJO 456
Description: Data will be recorded while subjects wear a 456 back brace manufactured by DJO Global
Study NCT05359705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen 456
Description: Data will be recorded while subjects wear a 456 back brace manufactured by Aspen Medical Products
Study NCT05359705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DJO 464
Description: Data will be recorded while subjects wear a 464 back brace manufactured by DJO Global
Study NCT05359705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen 464
Description: Data will be recorded while subjects wear a 464 back brace manufactured by Aspen Medical Products
Study NCT05658055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT05658055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT05658055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05658055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05658055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China
Study NCT05735262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active iTBS
Description: Each participant will receive 1800 pulse active iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
Study NCT05735262 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham iTBS
Description: Each participant will receive 1800 pulse sham iTBS (100% RMT) in each session, 3 sessions per day, 5 days per week for 8 weeks.
Study NCT05107791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stulln Eyedrops
Description: Stulln eyedrops will be applied to the anterior surface of cornea 3 times a day, 6 days a week. Half of participants (46) also receive accommodative training during the second stage (month) of the study while the rest maintains the Stulln eyedrops intervention.
Study NCT05107791 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thera Tears
Description: The eyedrops will be used in the identical manner as Stulln eyedrops.
Study NCT05575752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high temperature (32℃) group
Description: The exposure group will be exposed to high temperature (32℃) in a chamber for about 2 hours, resting during the whole periods.
Study NCT05575752 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: moderate temperature (22℃) group
Description: The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole periods.
Study NCT05526378 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Interventions
Description: Group 1 will be hear mother's voice before, during and after the procedure. Group 2 will be sniffed mother's breast milk before, during and after the procedure.~Group 3 will be skin contact with mother's before, during and after the procedure.
Study NCT05343364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Oral Tablet
Study NCT05156554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 6mg.
Study NCT05156554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF
Description: rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 5μg/kg once per day until the count of neutrophil>0.5×10\^9 /L.
Study NCT04760041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam nebulized
Description: midazolam nebulized
Study NCT04760041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam oral solution
Description: midazolam given oral
Study NCT05093985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation with blood flow restriction
Description: Neuromuscular electrical stimulation with blood flow restriction
Study NCT05636787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
Study NCT05636787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
Study NCT05636787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Efficacy of standard treatment melphalan will be compared to the combination melphalan with treosulfan
Study NCT03994770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Balanced Reach Assessment and Training Protocol
Description: Three one-hour training sessions for one week in the Balanced Reach Training Protocol
Study NCT05069545 — intervention group
Intervention type: DRUG
Intervention: Insulin degludec
Description: Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
Study NCT05069545 — intervention group
Intervention type: DRUG
Intervention: Fast-acting insulin aspart
Description: Introducing a NovoPen® 6 to patients with type 1 diabetes mellitus (T1DM), who are already being treated with Tresiba® and Fiasp®
Study NCT06181292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PHH-1V81
Description: booster of PHH-1V81
Study NCT06181292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty Omicron XBB1.5
Description: booster of Comirnaty Omicron XBB1.5
Study NCT06494332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and stretching programe
Description: It consists in: a serie of mobility exercises, which were used as warp-up; the mobility of the elbow, forearm, wrist and fingers of both upper limbs was worked on; and, exercises were performed to strengthen the muscles of both forearms.
Study NCT05088590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enfagrow® Neuropro Toddler Nutritional Drink
Description: Enfagrow® Neuropro Toddler Nutritional Drink to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
Study NCT05088590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pediasure® Grow & Gain Protein Shake for Kids
Description: Pediasure® Grow \& Gain Protein Shake for Kids to be consumed per day (equivalent to 40 mL per kg, rounded to the nearest ounce)
Study NCT06649422 — intervention group
Intervention type: DRUG
Intervention: Blinatumomab
Description: The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.